XENE · Insider trading · 13F holders · Congress trades
Xenon Pharmaceuticals Inc. (XENE)
Who is buying and selling XENE: company insiders on SEC Form 4, hedge funds and superinvestors on Form 13F, and members of Congress under the STOCK Act. Every figure links to the filing or page it comes from.
- 13F filers holding
- 38
- Insider buys, 90 days
- $1.7M
- Insider sales, 90 days
- $1.1M
- Congress trades, 12 months
- 0
XENE at a glance
- Between Aug 1, 2026 and Oct 29, 2026, 4 XENE insiders filed 2 open-market purchases worth $1.7M and 2 sales worth $1.1M on SEC Form 4; 1 of the sales were pre-planned under Rule 10b5-1.
- 38 13F filers hold XENE among their 50 largest positions, worth $1.8B combined, including Behzad Aghazadeh and James Flynn. The biggest bets by portfolio weight are TLS Advisors LLC (5.5%), NEXTBio Capital Management LP (5.1%) and Affinity Asset Advisors, LLC (4.8%). In their latest 13Fs, 1 manager opened a new position and 4 added to one.
- No member of Congress has disclosed a trade in XENE.
- XENE last closed at $37.54 on Oct 29, 2026.
XENE insider trading
Between Aug 1, 2026 and Oct 29, 2026, 4 XENE insiders filed 2 open-market purchases worth $1.7M and 2 sales worth $1.1M on SEC Form 4; 1 of the sales were pre-planned under Rule 10b5-1.
| Filed | Insider | Role | Trade | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Mortimer Ian | PRESIDENT & CEO, Director | Buy | 30,000 | $37.38 | $1.1M | SEC |
| Oct 1, 2026 | Kelly Thomas Patrick | Chief Financial Officer | Buy | 15,000 | $37.32 | $560K | SEC |
| Aug 31, 2026 | Kenney Christopher John | Chief Medical Officer | Sale10b5-1 | 7,068 | $60.25 | $426K | SEC |
| Aug 13, 2026 | Gannon Steven | Director | Sale | 10,000 | $64.06 | $641K | SEC |
Who owns XENE? Hedge funds and superinvestors
38 13F filers hold XENE among their 50 largest positions, worth $1.8B combined, including Behzad Aghazadeh and James Flynn. The biggest bets by portfolio weight are TLS Advisors LLC (5.5%), NEXTBio Capital Management LP (5.1%) and Affinity Asset Advisors, LLC (4.8%). In their latest 13Fs, 1 manager opened a new position and 4 added to one.
Superinvestors holding XENE: Behzad Aghazadeh 3.1% · James Flynn 1.2%
| Manager | % of portfolio | Value | Shares | Last quarter | 13F |
|---|---|---|---|---|---|
| Behzad AghazadehHedge fund | 3.1% | $348.7M | 5,777,777 | +0.0% shares | Q2 2026 |
| Polar Capital Holdings PlcHedge fund | 0.8% | $275.9M | 4,570,556 | +3.8% shares | Q2 2026 |
| Driehaus Capital Management LLCHedge fund | 1.5% | $266.7M | 4,418,557 | -1.6% shares | Q2 2026 |
| James FlynnHedge fund | 1.2% | $97.5M | 1,615,696 | +0.0% shares | Q2 2026 |
| Affinity Asset Advisors, LLCHedge fund | 4.8% | $96.3M | 1,595,000 | -4.8% shares | Q2 2026 |
| Siren, L.L.C.Investment manager | 1.6% | $79.6M | 1,318,564 | +0.0% shares | Q2 2026 |
| Braidwell LPHedge fund | 2.6% | $68.3M | 1,131,452 | -15.5% shares | Q2 2026 |
| Orbimed Advisors LLCHedge fund | 1.0% | $53.9M | 892,471 | -15.8% shares | Q2 2026 |
| Caligan Partners LPHedge fund | 2.6% | $53.7M | 889,944 | -36.1% shares | Q2 2026 |
| Vestal Point Capital, LPHedge fund | 1.0% | $42.3M | 700,000 | +9.4% shares | Q2 2026 |
| Rock Springs Capital Management LPHedge fund | 2.0% | $41.3M | 683,907 | -10.4% shares | Q2 2026 |
| First Turn Management, LLCInstitutional asset manager | 3.9% | $36.2M | 600,200 | -23.7% shares | Q2 2026 |
| Octagon Capital Advisors LPHedge fund | 2.7% | $29.6M | 490,000 | +0.0% shares | Q2 2026 |
| Novo Holdings A/sInvestment manager | 1.7% | $29.3M | 485,438 | +0.0% shares | Q2 2026 |
| Logos Global Management LPHedge fund | 1.2% | $27.2M | 450,000 | +0.0% shares | Q2 2026 |
| Trails Edge Capital Partners, LPHedge fund | 4.2% | $26.6M | 440,000 | +0.0% shares | Q2 2026 |
| Algert Global LLCInstitutional asset manager | 0.3% | $25.3M | 419,773 | — | Q2 2026 |
| Parkman Healthcare Partners LLCHedge fund | 2.5% | $24.0M | 397,379 | -20.1% shares | Q2 2026 |
| Nicholas Investment Partners, LPInvestment manager | 1.5% | $23.9M | 395,844 | +60.2% shares | Q2 2026 |
| Jones Hill Capital LPHedge fund | 4.7% | $22.2M | 367,900 | New | Q2 2026 |
| Soleus Capital Management, L.P.Hedge fund | 0.6% | $16.1M | 267,000 | -8.6% shares | Q2 2026 |
| DAFNA Capital Management LLCHedge fund | 2.9% | $15.1M | 250,772 | +0.0% shares | Q2 2026 |
| Nan Fung Trinity (HK) LtdInvestment manager | 1.5% | $15.0M | 247,765 | +0.0% shares | Q2 2026 |
| Redmile Group, LLCHedge fund | 0.9% | $13.8M | 229,374 | -12.7% shares | Q2 2026 |
| Patient Square Capital LPHedge fund | 2.1% | $13.3M | 220,000 | -3.1% shares | Q2 2026 |
| Eversept Partners, LPHedge fund | 0.6% | $11.9M | 196,532 | +51.7% shares | Q2 2026 |
| Silverarc Capital Management, LLCHedge fund | 1.3% | $11.3M | 186,821 | -5.5% shares | Q2 2026 |
| NEXTBio Capital Management LPHedge fund | 5.1% | $11.1M | 183,225 | +0.0% shares | Q2 2026 |
| Foresite Capital Management IV, LLCHedge fund | 3.3% | $9.7M | 160,000 | +0.0% shares | Q2 2026 |
| Sphera Funds Management Ltd.Hedge fund | 0.9% | $6.3M | 105,000 | -17.3% shares | Q2 2026 |
The 30 largest of 38 positions, by value. Each manager counts with its latest 13F (Q2 2026: 38). Screen XENE in the grand portfolio →
XENE stock trades by members of Congress
No member of Congress has disclosed a trade in XENE.
Analysis mentioning XENE
Posts from the blog that cover Xenon Pharmaceuticals Inc., newest first.
XENE questions and answers
Are insiders buying XENE stock?
Between Aug 1, 2026 and Oct 29, 2026, 4 XENE insiders filed 2 open-market purchases worth $1.7M and 2 sales worth $1.1M on SEC Form 4; 1 of the sales were pre-planned under Rule 10b5-1.
Which hedge funds own XENE?
38 13F filers hold XENE among their 50 largest positions, worth $1.8B combined, including Behzad Aghazadeh and James Flynn. The biggest bets by portfolio weight are TLS Advisors LLC (5.5%), NEXTBio Capital Management LP (5.1%) and Affinity Asset Advisors, LLC (4.8%). In their latest 13Fs, 1 manager opened a new position and 4 added to one.
Has Congress traded XENE?
No member of Congress has disclosed a trade in XENE.
Who is the largest holder of XENE?
Among 13F filers, Behzad Aghazadeh reports the largest XENE position, $348.7M (5,777,777 shares) in its Q2 2026 13F. The biggest bet by portfolio weight is TLS Advisors LLC's: 5.5% of its portfolio.
Cite or share this
Free to use with a link back. The data updates every filing day.